Details for New Drug Application (NDA): 208647
✉ Email this page to a colleague
NDA 208647 describes EZALLOR SPRINKLE, which is a drug marketed by Sun Pharm and is included in one NDA. There is one patent protecting this drug. Additional details are available on the EZALLOR SPRINKLE profile page.
The generic ingredient in EZALLOR SPRINKLE is rosuvastatin calcium. There are forty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the rosuvastatin calcium profile page.
The generic ingredient in EZALLOR SPRINKLE is rosuvastatin calcium. There are forty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the rosuvastatin calcium profile page.
Summary for 208647
| Tradename: | EZALLOR SPRINKLE |
| Applicant: | Sun Pharm |
| Ingredient: | rosuvastatin calcium |
| Patents: | 1 |
Medical Subject Heading (MeSH) Categories for 208647
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 5MG BASE | ||||
| Approval Date: | Dec 18, 2018 | TE: | RLD: | Yes | |||||
| Patent: | 10,413,543 | Patent Expiration: | Feb 12, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Dec 18, 2018 | TE: | RLD: | Yes | |||||
| Patent: | 10,413,543 | Patent Expiration: | Feb 12, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 20MG BASE | ||||
| Approval Date: | Dec 18, 2018 | TE: | RLD: | Yes | |||||
| Patent: | 10,413,543 | Patent Expiration: | Feb 12, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
